H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Genetics and Molecular Biology D-index 135 Citations 69,292 371 World Ranking 103 National Ranking 4

Research.com Recognitions

Awards & Achievements

2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • Cancer

Kohei Miyazono mostly deals with Cell biology, SMAD, Signal transduction, Bone morphogenetic protein and Molecular biology. His Cell biology research includes themes of Endocrinology, Ubiquitin and Cellular differentiation. His study in SMAD is interdisciplinary in nature, drawing from both R-SMAD, Transcription factor and Transcription.

The study incorporates disciplines such as Cancer research, Kinase and Cytokine in addition to Signal transduction. The Bone morphogenetic protein study combines topics in areas such as Bone morphogenetic protein 2 and Osteoblast. The concepts of his Molecular biology study are interwoven with issues in Transfection, Complementary DNA, Molecular cloning and Receptor, Cell surface receptor.

His most cited work include:

  • TGF-beta signalling from cell membrane to nucleus through SMAD proteins (3313 citations)
  • Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. (2078 citations)
  • Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways (2000 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Cell biology, Transforming growth factor, Molecular biology, Cancer research and Signal transduction. His Cell biology study incorporates themes from Receptor, Endocrinology and Bone morphogenetic protein. He combines subjects such as Internal medicine, Bone morphogenetic protein 2 and Cellular differentiation with his study of Bone morphogenetic protein.

His Transforming growth factor research is multidisciplinary, incorporating perspectives in Transcriptional regulation, Transforming growth factor, beta 3, Growth factor, Phosphorylation and Regulation of gene expression. His studies deal with areas such as Cancer cell, Cancer, Metastasis, Cell culture and Immunology as well as Cancer research. His SMAD research is multidisciplinary, incorporating elements of R-SMAD, Ubiquitin and Transcription factor.

He most often published in these fields:

  • Cell biology (54.15%)
  • Transforming growth factor (33.23%)
  • Molecular biology (29.39%)

What were the highlights of his more recent work (between 2012-2021)?

  • Cancer research (26.68%)
  • Cell biology (54.15%)
  • Transforming growth factor (33.23%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Cancer research, Cell biology, Transforming growth factor, Cancer and Cancer cell. His study in Cancer research is interdisciplinary in nature, drawing from both Cell culture, Transcription factor, Receptor, Metastasis and Regulation of gene expression. Kohei Miyazono focuses mostly in the field of Transcription factor, narrowing it down to matters related to Chromatin immunoprecipitation and, in some cases, Molecular biology.

His Receptor research incorporates themes from Angiogenesis and Kinase. His biological study spans a wide range of topics, including BMPR2, Bone morphogenetic protein, Embryonic stem cell and Cellular differentiation. A large part of his Transforming growth factor studies is devoted to SMAD.

Between 2012 and 2021, his most popular works were:

  • TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology (349 citations)
  • Regulation of TGF-β Family Signaling by Inhibitory Smads. (142 citations)
  • MicroRNA regulons in tumor microenvironment (115 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • Cancer

His scientific interests lie mostly in Cancer research, Transforming growth factor, Cell biology, Cancer and SMAD. Kohei Miyazono interconnects Cell culture, Cancer cell, Transcriptional regulation, Metastasis and Regulation of gene expression in the investigation of issues within Cancer research. As a member of one scientific family, Kohei Miyazono mostly works in the field of Transforming growth factor, focusing on Signal transduction and, on occasion, Receptor and Endocrinology.

The concepts of his Cell biology study are interwoven with issues in Genetics, Cellular differentiation, CXCL16, Regulator and Bone morphogenetic protein. His Cancer study combines topics in areas such as Transforming growth factor beta, Obesity, Stem cell and Type 2 diabetes. His work in SMAD tackles topics such as Chromatin immunoprecipitation which are related to areas like Transcription factor, Molecular biology, Chromatin, Scaffold/matrix attachment region and ChIA-PET.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

Carl-Henrik Heldin;Kohei Miyazono;Peter ten Dijke.
Nature (1997)

4767 Citations

Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1.

Masao Saitoh;Hideki Nishitoh;Makiko Fujii;Kohsuke Takeda.
The EMBO Journal (1998)

2711 Citations

Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways

Hidenori Ichijo;Eisuke Nishida;Kenji Irie;Peter ten Dijke.
Science (1997)

2600 Citations

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

H. Cabral;Y. Matsumoto;K. Mizuno;Q. Chen.
Nature Nanotechnology (2011)

1866 Citations

Modulation of microRNA processing by p53

Hiroshi I. Suzuki;Kaoru Yamagata;Koichi Sugimoto;Takashi Iwamoto.
Nature (2009)

1488 Citations

ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis

Kei Tobiume;Atsushi Matsuzawa;Takumi Takahashi;Hideki Nishitoh.
EMBO Reports (2001)

1306 Citations

Smad6 inhibits signalling by the TGF-β superfamily

Takeshi Imamura;Masao Takase;Ayako Nishihara;Eiichi Oeda.
Nature (1997)

1303 Citations

TGFβ signalling: a complex web in cancer progression

Hiroaki Ikushima;Kohei Miyazono.
Nature Reviews Cancer (2010)

1275 Citations

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.

Atsuhito Nakao;Takeshi Imamura;Takeshi Imamura;Serhiy Souchelnytskyi;Masahiro Kawabata.
The EMBO Journal (1997)

1231 Citations

Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin

Toshio Kitamura;Tsuyoshi Tange;Takashi Terasawa;Shigeru Chiba.
Journal of Cellular Physiology (1989)

1214 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Kohei Miyazono

Hidenori Ichijo

Hidenori Ichijo

University of Tokyo

Publications: 193

Carl-Henrik Heldin

Carl-Henrik Heldin

Uppsala University

Publications: 134

Peter ten Dijke

Peter ten Dijke

Leiden University Medical Center

Publications: 121

Aristidis Moustakas

Aristidis Moustakas

Uppsala University

Publications: 105

Joan Massagué

Joan Massagué

Memorial Sloan Kettering Cancer Center

Publications: 100

Jeffrey L. Wrana

Jeffrey L. Wrana

Lunenfeld-Tanenbaum Research Institute

Publications: 98

Kazunori Kataoka

Kazunori Kataoka

University of Tokyo

Publications: 93

Junji Yodoi

Junji Yodoi

Kyoto University

Publications: 85

Rik Derynck

Rik Derynck

University of California, San Francisco

Publications: 85

Yuji Mishina

Yuji Mishina

University of Michigan–Ann Arbor

Publications: 82

Petra Knaus

Petra Knaus

Freie Universität Berlin

Publications: 82

Nicholas W. Morrell

Nicholas W. Morrell

University of Cambridge

Publications: 79

Kinichi Nakashima

Kinichi Nakashima

Kyushu University

Publications: 74

Anita B. Roberts

Anita B. Roberts

National Institutes of Health

Publications: 73

Daniel B. Rifkin

Daniel B. Rifkin

New York University

Publications: 72

Kohsuke Takeda

Kohsuke Takeda

Nagasaki University

Publications: 69

Something went wrong. Please try again later.